Trial Profile
Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Agitation; Alzheimer's disease; Dementia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MAGD; MAGD-Genes
- 30 Jan 2014 Accruel to date is 93% according to United Kingdom Clinical Research Network record (3986).
- 22 Oct 2012 New source identified and integrated (ISRCTN: Current Controlled Trials: 24953404).
- 18 Feb 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record (9420).